Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:55 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
NCT02842125 · MultiVir, Inc. · PHASE1/PHASE2 · terminated · last registry update 2020-06-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Arm C rolled into parallel study; Arms A and B halted for greater efficacy in Arm C” | – | Registry record, MultiVir, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TYMS within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-10-29Phase 3 first posted: Pfizer, Encorafenib + Cetuximab (NCT04607421)
- 2020-10-14Phase 3 first posted: Stanford University, Durvalumab + Carboplatin (NCT04585490)
- 2020-09-16Phase 3 first posted: AstraZeneca, Durvalumab + Placebo (NCT04550260)
- 2020-09-04Phase 3 first posted: Janssen Research & Development, LLC, Amivantamab + Pemetrexed (NCT04538664)
- 2020-07-31Phase 3 first posted: Ralf Hofheinz, mFOLFOX (neoadjuvant) + XELOX (neoadjuvant) (NCT04495088)
- 2020-04-06Phase 3 first posted: PrECOG, LLC., Durvalumab + Standard Chemotherapy (NCT04334759)
- 2020-02-13Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT04267848)
- 2020-02-05Results posted on the registry: National Cancer Institute (NCI), Cediranib Maleate + Cisplatin (NCT01064648)
- 2020-01-30Phase 3 first posted: ECOG-ACRIN Cancer Research Group, Capecitabine + Fluorouracil (NCT04248452)
- 2019-12-24Phase 3 first posted: Merck Sharp & Dohme LLC, pembrolizumab + placebo (NCT04210115)
- 2019-12-11Phase 3 first posted: Eli Lilly and Company, Selpercatinib + Carboplatin (NCT04194944)
- 2019-11-15Results posted on the registry: National Cancer Institute (NCI), Bevacizumab + Carboplatin (NCT00588770)
- 2019-10-16Phase 3 first posted: Takeda, TAK-788 + Pemetrexed (NCT04129502)
- 2019-09-19Phase 3 first posted: Alliance for Clinical Trials in Oncology, Bevacizumab + Oxaliplatin (NCT04094688)
- 2019-09-17Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT04092283)
- 2019-09-10Results posted on the registry: Incyte Corporation, Pembrolizumab + Epacadostat (NCT03358472)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision